Kornimate/medical-research-clean huggingface dataset:
a study of ly3473329 in adult participants with elevated lipoprotein(a) at high risk for cardiovascular events

Conditions: Lipoprotein Disorder

Summary: the main purpose of this study is to evaluate the efficacy and safety of ly3473329 in adult participants with elevated lp(a) at high risk for cardiovascular events.


Eligibility criteria:
inclusion criteria: * participants must be at least 40 years old * participants with lp(a) ≥175 nmol/l at randomization, measured at the central laboratory. * high risk for cardiovascular events defined as documented coronary artery disease (cad), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ascvd) risk equivalents (familial hypercholesterolemia or type 2 diabetes). * participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period. * lipid-lowering drugs * testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone * have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive. * males who agree to use highly effective or effective methods of contraception may participate in this trial. * women of childbearing potential (wocbp) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (wnocbp) may participate in this trial. exclusion criteria: * have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data. * any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization: * major surgery * coronary, carotid, or peripheral arterial revascularization * stroke or transient ischemic attack * myocardial infarction or unstable angina * acute limb ischemia * have, in the 6 months prior to day 1, uncontrolled type 1 or type 2 diabetes * have uncontrolled hypertension

Keywords: atherosclerotic cardiovascular disease ascvd dyslipidemia lipoprotein(a) lp(a) cardiovascular cardiovascular disease cholesterol hyperlipidemia
cannabidiol in youth alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: the goal of this study is to test cannabidiol (cbd) as a potentially effective candidate medication for youth alcohol use disorder (aud). to accomplish this goal, this study will use a randomized, double-blind, within-subjects crossover design. in counterbalanced order, 50 youth (ages 16-22) will receive 600 mg of cbd or placebo three hours before a neuroimaging and behavioral assessment paradigm. the total amount of time the participant will be in the study is approximately one month.


Eligibility criteria:
age 16 to 22. does or does not drink alcohol.
the cerebellum as a potential treatment site for pd motor symptoms

Conditions: Parkinson's Disease

Summary: the role of the cerebello-thalamo-cortical loop in the generation of tremor, gait impairments and postural instability has been made evident. the current study will use a magstim rapid 2 to deliver rtms with the aim of modulating the activity in the vermal/paravermal region of the cerebellum, and consequently the cerebello-thalamo-cortical pathway. analysis of the effects of an acute session of stimulation will be made to determine the therapeutic potential of the protocol. motor symptom improvement will be assessed immediately following stimulation to detect motor symptom improvement up to one hour following stimulation, providing insight into the effectiveness of the protocol to produce benefits which outlast the period of stimulation. participants will each receive one session of stimulation in the on state of medication. a pre-assessment will be performed before beginning the session and a post-assessment will be performed immediately following stimulation. there will be two groups, which will both undergo the exact same protocol, however one group will receive real stimulation, and one group will receive sham stimulation.


Eligibility criteria:
inclusion criteria: * diagnosed with idiopathic parkinson's disease * ability to walk 10 metres unassisted * ability to stand for 5 minutes unassisted * understand verbal instructions in english exclusion criteria: * presence of brain implants (aneurysm clips, deep brain stimulation electrodes) * cochlear implants * diagnosed with vascular parkinson's disease * history or increased risk of seizure * severe dyskinesia of neck muscles
improving the diagnosis of sexually transmitted infections in emergency rooms

Conditions: Sexually Transmitted Infection

Summary: a point-of-care laboratory (poc) was set at north hospital, marseille, france for the diagnosis in less than two hours of sexually transmitted infections caused by known pathogens, close to the reception of emergency service. in this instance 30% of patients have no etiological diagnosis after the poc sexually infection transmitted tests . most sexually transmitted infections can be diagnosed from an anal swab which is not routinely performed. in this study, we suggest to test the hypothesis that anal swab in addition to the routine genital swab would increase by at least 5% the diagnosis capacity of sexually transmitted infections after the poc tests.


Eligibility criteria:
inclusion criteria: * patient admitted for sexually transmitted infection in emergency room requiring a microbiological examination with a "sexually transmitted infection poc kit" * patient who freely signed the informed consent form * patient affiliated to a social security regime exclusion criteria * pregnant or breastfeeding women * adult patient under guardianship * patient deprived with liberty under court order * patient refusing or unable to sign the informed consent form
comparison between ldct with dl recontruction and standard dose ct

Conditions: Liver Metastases

Summary: this prospective study aims to perform intra-individual comparison of the image quality between low dose liver ct with deep learning reconstruction and standard dose liver ct with iterative reconstruction in patients with liver metastasis.


Eligibility criteria:
inclusion criteria: * patients with underlying malignancy and suspicion of liver metastasis * patients with known liver metastasis and on follow-up * and scheduled for contrast enhanced abdomen ct * signed informed consent exclusion criteria: * absolute or relative contra-indication for contrast-enhanced ct * diffuse infiltrative liver lesion or multiple (\> 10) metastases

Keywords: ct metastasis liver
safety and efficacy of the surpass evolve flow diverter in treating intracranial aneurysms

Conditions: Intracranial Arterial Aneurysm

Summary: safety and efficacy of the surpass evolve flow diverter in treating intracranial aneurysms

this study aims to retrospectively evaluate the efficacy and safety of the surpass evolve flow diverter in treating complex intracranial aneurysms. it seeks to assess long-term outcomes and complication rates while analyzing the impact of patient characteristics and aneurysm types on treatment effectiveness. by collecting data from multiple centers, the study ensures broad representativeness, ultimately providing valuable insights for clinical management on a global scale.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm. 2. imaging studies confirming suitability for surpass evolve flow diverter treatment. 3. aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm). 4. at least six months of follow-up data available post-treatment. exclusion criteria: 1. patients with acutely ruptured aneurysms or significant bleeding. 2. patients with incomplete data or insufficient follow-up records.

Keywords: intracranial arterial aneurysm surpass evolve flow diverter
evaluation of remote monitoring of liver cirrhosis patients

Conditions: Liver Cirrhosis

Summary: the goal of this longitudinal prospective study is to investigate disease course in patients with liver cirrhosis treated in hospitals that implemented a remote monitoring care pathway as part of their standard liver cirrhosis care pathway. participants will be asked to share their medical data and remote monitoring data. therefore, this study does not contain an intervention.


Eligibility criteria:
inclusion criteria: * liver cirrhosis diagnosis, based on liver biopsy, fibroscan (elastography), radiographic imaging and/or clinical criteria according to applied guidelines at the time of inclusion * age 18 years or older * treated at gastroenterology department exclusion criteria: * patients who have declined participation in scientific studies.

Keywords: digital health remote monitoring ehealth mhealth telehealth
diffusion mri for pancreatic adenocarcinoma

Conditions: Pancreatic Adenocarcinoma

Summary: the detection of small liver metastases represents a major challenge during the staging process of patients with pancreatic adenocarcinoma. currently, thoraco-abdominopelvic ct represents the established imaging modality for selecting patients with pancreatic adenocarcinoma for curative surgery. however, despite its performance, 13% to 23% of patients undergoing a surgical procedure are finally found to have an unresectable disease because of arterial involvement, peritoneal carcinomatosis, or the existence liver metastasis that had not been detected by preoperative workup. compared to ct, diffusion-weighted mri provides a better contrast resolution for soft tissue and liver imaging, and thus leads to a better detection of focal liver lesions. hence, it could be hypothesized that the use of dw-mri in patients with potentially resectable pa may improve the selection process of candidates for curative pancreatic resection by increasing the detection of lm undiagnosed by traditional preoperative work-up


Eligibility criteria:
inclusion criteria: * age \> 18 year old, * no general contraindication for pancreatic surgery, * pancreatic mass suspected or demonstrated to be a pancreatic adenocarcinoma, * cap ct of excellent technical quality showing a pancreatic tumor deemed resectable or border line (portal and/or superior mesenteric venous circumferential involvement \< 180° * resectability confirmed by a medical/surgical multidisciplinary review, * if neoadjuvant therapy was applied, patients were included in the study: only the second evaluation will be considered. * informed consent prepared and signed. exclusion criteria: * locally advanced pancreatic adenocarcinoma (involvement \> 180°in circumference of superior mesenteric venous (smv) or portal vein, superficial vein thrombosis, superior mesenteric artery (sma) involvement \< 180°) * unresectable tumour (circumferential involvement \> 180 ° of the sma, involvement of the celiac artery, thrombosis of the portal vein or vena cava, or complete vms thrombosis * metastasis of any organ visible on thoraco-abdominopelvic ct scan * time lag exceeding 21 days between diffusion-weighted mri and surgery * contraindication for an mri
antenatal corticoid therapy for late preterm babies

Conditions: Hyaline Membrane Disease; Transient Tachypnea

Summary: this study aims to determine the effectiveness of antenatal corticosteroid therapy in late preterm babies. the investigators hypothesis is corticoid accelerates fetal lung maturation even after 34 weeks and reduces risk of respiratory distress syndrome and other neonatal morbidities.

late preterm babies have important morbidity when compared with term babies, with oxygen requirement and more days of hospitalization. if antenatal corticosteroid therapy is necessary for fetal lung maturation after 34 weeks, it remains to be established. the systematic review with metanalysis in cochrane library includes a small number of late preterm babies and no conclusion about effectiveness of corticoid therapy in this setting could be drawn. our hypothesis is that antenatal corticosteroid therapy is effective to prevent respiratory disease and morbidity in late preterm babies and this study will be carried out to evaluate this question.

Eligibility criteria:
inclusion criteria: * pregnancy between 34 and 36 weeks * confirmed gestational age (lmp, usg) * alive fetus * imminent risk of preterm delivery exclusion criteria: * multiple pregnancy * major fetal malformations * comproved fetal lung maturity * maternal or fetal indication for immediate interruption of pregnancy * maternal hemorrhagic syndromes (placenta previa, abruptio placenta) * chorioamnionitis * chronic use of corticosteroids * previous use of corticosteroids for fetal lung maturation in the current pregnancy

Keywords: corticoid therapy fetal lung maturation late preterm respiratory distress syndrome neonatal death
study to investigate the effects single oral dose of azd1386 (capsaicin)

Conditions: Capsaicin Evoked Pain; Heat Sensitivity

Summary: a double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of azd1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers


Eligibility criteria:
inclusion criteria: * clinical normal physical findings, including bp, pulse rate \>45 bpm, ecg and laboratory assessments * body mass index (bmi) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg. * non-fertile females exclusion criteria: * history of hypersensitivity, allergy or atopic/skin disease as judged by investigator. * history of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator.

Keywords: proof of mechanism capsaicin evoked pain
cloud-r hae registry

Conditions: ANGIOEDEMA

Summary: angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. in this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. but there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. these angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. this registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.

the grenoble center is the registry coordinator at the national level. it will contract directly with the cloud r company and will be in charge of coordinating the associated centers. it will therefore send the necessary documents for the good execution of the study, will ask each center to respect the current french regulatory, will organize and finance the set-up of the register in the associated centers. the coordinating center will also centralize requests for data, publications or creation of additional ecrf pages of associated centers. it will be able to organize a national scientific committee every 6 months. it will thus be the link between the french centers, the scientific committee of the registry and the company cloud r. the coordinating center will also be responsible for enter and reliability of patient data from it center, as well as the associated centers. role of associated centers associated centers will be responsible for capturing and data reliability of their patients in ecrf, they will also create a personal account for each patient so that it can download the application "cloud r hae carnet de suivi". investigators referent patient will have validated at each visit or after contact with the patient crisis returned to the patient via it electronic diary. associated centers will keep informed twice a year the coordinator center of the state of inclusions in the register.

Eligibility criteria:
inclusion criteria: * any patient with isolated angioedema without associated wheals. * patients with hereditary angioedema with or without c1 deficiency. * major patient with consent (signature) * minor patient whose parents / legal guardians have given their consent (signature) exclusion criteria: * patient unable to give consent. * wheals with angioedema
high dose versus standard dose proton pump inhibitor (ppi) in high-risk bleeding peptic ulcers after combined endoscopic treatment

Conditions: Endoscopy; Peptic Ulcer; Bleeding; Proton Pump Inhibitors

Summary: the study was designed to evaluate the efficacy an adjuvant use of standard dose or high dose of proton pump inhibitor after combined endoscopic hemostasis therapy.

acute peptic ulcer bleeding remains the most common cause of acute upper gastrointestinal bleeding. endoscopy serves as a tool for initial diagnosis and triage and also a tool for immediate hemostasis, especially for high-risk lesions. high-risk lesions include peptic ulcers with active spurting vessel, oozing vessel, or nbvv, nonbleeding visible vessel. current modalities of endoscopic hemostasis include epinephrine injection, endoscopic coaptive thermocoagulation, hemoclipping. endoscopic hemostasis has been documented by a number of clinical studies to be effective in decreasing rebleeding, need for emergency surgery, decreasing hospitalization days. current evidence also shows that combination therapy with epinephrine injection and heater probe thermocoagulation/hemo-clip hemostasis is more effective than epinephrine injection alone or than heater probe thermocoagulation alone, or than hemoclip hemostasis alone. studies showed a high dose intravenous proton pump inhibitor infusion after initial endoscopic hemostasis reduced recurrent ulcer bleeding. however, it was still controversial whether an adjuvant use of standard-dose proton pump inhibitor therapy to endoscopic therapy had similar benefit. we hypothesized that an adjuvant use of standard dose of proton pump inhibitor after combined endoscopic hemostasis therapy offer similar benefit as high dose proton pump inhibitor did.

Eligibility criteria:
inclusion criteria: * adults aged above 16 years old with acute nonvariceal upper gastrointestinal bleeding * read, agree to attend the study, and signed informed consent indicated to receive esophagogastroduodenoscopy(egd) * peptic ulcers with high risk lesions (active bleeding: spurting, oozing peptic ulcers. ulcers with nbvv: nonbleeding visible vessel) exclusion criteria: * unable to receive egd (unable to open mouth, upper gastrointestinal obstruction) * bleeding tendency (platelet \ 2, ongoing use of heparin or coumadin) * gastric malignancy * myocardial infarction within recent one week * recent cerebrovascular event within recent one week * pregnancy * refuse to attend the study * known allergy history to epinephrine or pantoprazole

Keywords: endoscopic treatment peptic ulcer bleeding thermocoagulation proton pump inhibitors
gingival crevicular fluid levels of protein carbonyl following the use of lycopene in chronic periodontitis

Conditions: Chronic Periodontitis

Summary: effect of locally delivered antioxidants as an adjunct to non-surgical periodontal therapy on gcf level of oxidative stress marker; protein carbonyl

the study was designed as a randomized controlled clinical trial. total subjects selected were allocated into three study groups, group i (test group), group ii (positive control group) and group iii (negative control group). group i: included 8 patients with severe chronic periodontitis managed by scaling and root planing and local delivery of lycopene loaded in solid lipid microparticles. group ii: included 8 patients with severe chronic periodontitis managed by scaling and root planing only. group iii: included 8 patients with clinically healthy periodontium. protein carbonyl biomarker level and clinical parameters were assisted to evaluate the effect of lycopene as an adjunct to scaling and root planing.

Eligibility criteria:
inclusion criteria: * all subjects were free from any systemic diseases. * subjects for group i and ii were suffering from severe chronic periodontitis (armitage et al., 1999). * group iii included subjects with clinically healthy periodontium. * all subjects were between 35-60 years old. * both genders were included. * subjects were able to return for follow up visits. * subjects agreed to sign a written consent after the nature of the study was explained. exclusion criteria: * history of scaling and root planing or periodontal surgery \< 6 months prior to initiation of the study. * history of administration of antimicrobial drugs or over the counter antioxidants like vit c, vit b, β-carotene \< 6 months prior to the baseline examination. * subjects who reported any side effects or drug allergies from antioxidants. * subjects with mobile teeth, abscesses and defected restorations related to the affected sites. * subjects with para-functional habits. * pregnant and lactating females. * smokers, alcoholic and drug abusers. * prisoner. * mentally retarded patients.

Keywords: lycopene chronic periodontitis protein carbonyl
ensite precision 2.1 feasibility study

Conditions: Arrhythmias

Summary: the objective is to demonstrate feasibility of new 'magnetic primary' catheter tracking algorithms within the velocity research platform (vrp) by assessing the frequency of shift/drift during ablation compared to the current commercial ensite precision 2.0.1 the secondary objective is to evaluate catheter rendering in the vrp system.

this is an acute, multi-center, observational, prospective feasibility study with up to 80 patients at up to 5 centers in europe. data will be simultaneously collected on both the ensite precision 2.0.1 and vrp mapping systems for the entire duration of the ep mapping and ablation procedure. this study will not require significant change to the current clinical workflow of the mapping and ablation procedure. the vrp operator will observe both displays in real-time and will enter extensive electronic annotations to the vrp data stream to facilitate retrospective analysis. examples of annotations include drug administration, patient movement, and the introduction of devices such as an intracardiac echography (ice) catheter which are not visible on the ensite mapping system. if/when the vrp operator notices events which might be better understood with additional data, he/she might ask the physician to hold a catheter in a stable position for an extra few seconds and/or move the catheter to another position. examples of such events include catheters appearing outside the 3d model and unrealistic catheter shapes on either display. compliance with such requests is optional and subject to physician preference. retrospective data analysis will focus on characterization of the following: * occurence rates and potential causes for shift and drift. * frequency and severity of discrepancies between impedance and magnetic coordinates. * positions of catheters relative to the 3d model. * positions of catheters relative to each other, comparing to fluoroscopic images when available. * shapes of catheters on the research system as the catheters are moved to different locations. * final geometry apprearance on the vrp. * voltage and timing maps appearance on the vrp.

Eligibility criteria:
inclusion criteria: * patients indicated for a cardiac ep study and ablation procedure using a 3d mapping system. * over 18 years of age * ability to provide informed consent for study participation and be willing and able to comply with the protocol described evaluations. exclusion criteria: * pregnant or possibly pregnant patients